Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 2/20 | 0.61 |
| ▸ | CPA1 | P15085 | 2/20 | 0.50 |
| ▸ | CPA2 | P48052 | 1/20 | 0.50 |
| ▸ | CPA4 | Q9UI42 | 1/20 | 0.50 |
| ▸ | OPRD1 | P41143 | 6/20 | 0.49 |
| ▸ | BACE1 | P56817 | 1/20 | 0.49 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.49 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.47 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.47 |
| ▸ | MMP9 | P14780 | 1/20 | 0.46 |
| ▸ | MMP8 | P22894 | 1/20 | 0.46 |
| ▸ | MME | P08473 | 1/20 | 0.46 |
| ▸ | ACE | P12821 | 1/20 | 0.46 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2314769 | 1.00 | CASP1 (0.61) | CASP1CPA1CPA2CPA4OPRD1 | |
| SCHEMBL9292479 | 0.92 | CPA1 (0.55) | CASP1CPA1CPA2CPA4OPRD1 | |
| SCHEMBL9334753 | 0.92 | CPA1 (0.55) | CASP1CPA1CPA2CPA4OPRD1 | |
| SCHEMBL14370014 | 0.91 | CASP1 (0.60) | CASP1CPA1CPA2CPA4OPRD1 | |
| SCHEMBL646595 | 0.90 | CASP1 (0.55) | CASP1CPA1CPA2CPA4OPRD1 | |
| SCHEMBL5686896 | 0.90 | ACE (0.55) | CASP1CPA1CPA2CPA4OPRD1 | |
| SCHEMBL5686910 | 0.90 | ACE (0.55) | CASP1CPA1CPA2CPA4OPRD1 | |
| SCHEMBL24310822 | 0.89 | CASP1 (0.63) | CASP1CPA1CPA2CPA4OPRD1 | |
| SCHEMBL7752844 | 0.89 | CASP1 (0.55) | CASP1CPA1CPA2CPA4OPRD1 | |
| SCHEMBL5689768 | 0.88 | CASP1 (0.59) | CASP1CPA1CPA2CPA4OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9365612-B2 | Caspase inhibitors | UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2016-06-14 | — | — | US | disclosed |
| US-20120294843-A1 | CASPASE INHIBITORS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2012-11-22 | — | — | US | disclosed |
| WO-2011094426-A1 | CASPASE INHIBITORS | THE UNITED STATE OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES (US) | 2011-08-04 | — | — | WO | disclosed |
| EP-0979241-B1 | (3R)-3-AMINO-4-CARBOXYBUTYRALDEHYDE DERIVATIVES INHIBITING THE RELEASE OF INTERLEUKIN-1/BETA | IVAX DRUG RES INST LTD (HU) | 2006-03-01 | — | — | EP | disclosed |
| US-6593300-B1 | Inhibitors of the interleukin-1 beta converting enzyme | GYOGYSZERKUTATO INTEZET KFT. (HU) | 2003-07-15 | — | — | US | disclosed |
| US-6348570-B1 | TETRAPEPTIDES; DIAGNOSING AND MONITORING INFLAMMATORY, NERVOUS SYSTEM, SKIN, CARDIOVASCULAR, RESPIRATORY SYSTEM, GASTROINTESTINAL, UROGENITAL AND IMMUNE DISORDERS; EVALUATING INHIBITORS | MERCK & CO., INC. | 2002-02-19 | — | — | US | disclosed |
| EP-0979241-A1 | (3R)-3-AMINO-4-CARBOXYBUTYRALDEHYDE DERIVATIVES INHIBITING THE RELEASE OF INTERLEUKIN-1/BETA | GYOGYSZERKUTATO INTEZET KFT. (HU) | 2000-02-16 | — | — | EP | disclosed |
| US-5866545-A | ANTIINFLAMMATORY AGENTS; NERVOUS SYSTEM DISORDERS; GASTROINTESTINAL DISORDERS; UROGENITAL DISORDERS | MERCK & CO., INC. (US) | 1999-02-02 | — | — | US | disclosed |
| WO-1998049189-A1 | (3R)-3-AMINO-4-CARBOXYBUTYRALDEHYDE DERIVATIVES INHIBITING THE RELEASE OF INTERLEUKIN-1/BETA | Gyógyszerkutató Intézet Kft. (HU) | 1998-11-05 | — | — | WO | disclosed |
| EP-0519748-B1 | Peptidyl derivatives as inhibitors of interleukin-1B converting enzyme | MERCK & CO INC (US) | 1998-09-02 | — | — | EP | disclosed |
| US-5434248-A | Peptidyl derivatives as inhibitors of interleukin-1β converting enzyme | MERCK & CO., INC. (US) | 1995-07-18 | — | — | US | disclosed |
| WO-1995005192-A1 | SUBSTITUTED KETONE DERIVATIVES AS INHIBITORS OF INTERLEUKIN-1β CONVERTING ENZYME | MERCK & CO., INC. (US) | 1995-02-23 | — | — | WO | disclosed |
| US-5278061-A | Affinity chromatography matrix useful in purifying interleukin-1β converting enzyme | MERCK & CO., INC. (US) | 1994-01-11 | — | — | US | disclosed |
| WO-1993014777-A1 | PEPTIDYL DERIVATIVES AS INHIBITORS OF INTERLEUKIN-1β CONVERTING ENZYME | MERCK & CO., INC. (US) | 1993-08-05 | — | — | WO | disclosed |
| EP-0547699-A1 | Peptidyl derivatives as inhibitors of interleukin-1B converting enzyme | MERCK & CO. INC. (US) | 1993-06-23 | — | — | EP | disclosed |
| EP-0533226-A2 | Novel chromophore containing compounds | MERCK & CO. INC. (US) | 1993-03-24 | — | — | EP | disclosed |
| EP-0529713-A1 | Affinity chromatography matrix useful in purifying interleukin-1B converting enzyme | MERCK & CO. INC. (US) | 1993-03-03 | — | — | EP | disclosed |
| EP-0528487-A2 | Novel chromophore containing compounds | MERCK & CO. INC. (US) | 1993-02-24 | — | — | EP | disclosed |
| EP-0519748-A2 | Peptidyl derivatives as inhibitors of interleukin-1B converting enzyme | MERCK & CO. INC. (US) | 1992-12-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120294843-A1 | CASPASE INHIBITORS | CASP1, CASP7, CASP14 | CASP1 1/4885CPA1 149/4885CPA2 429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.